Which GLP-1 Provider Is Right for Me? 9 Matches (2026)

If you’ve already opened three “best of” lists and you’re still asking which GLP-1 provider is right for me, you don’t have a research problem — you have a personalization problem. Every ranking page sorts by who’s best on average. This page sorts by you.

The right GLP-1 provider depends on five things about your situation: whether you have commercial insurance, whether you want FDA-approved or compounded medication, your preferred format (injection, pill, or sublingual), your state, and how you want to pay. Once those five answers are clear, the provider almost picks itself.

If you have commercial insurance and want FDA-approved Wegovy, Zepbound, or Foundayo, Ro is the cleanest first stop — they handle prior-authorization paperwork. If you’re paying cash and want bundled all-in pricing with 24/7 support, MEDVi ($179 first month). If you want the option to switch between compounded and brand-name on one platform with a same-price-at-every-dose guarantee, Eden ($129–$149 first month). Not sure which row describes you? The 60-second match quiz below sorts it.

Here’s the part most “best of” lists don’t tell you: every provider solves one problem really well and creates a different one in the process. We’ll walk you through which tradeoff fits you — based on your situation, not ours.

Find your row in 5 seconds

What we actually verified for this guide

• ✅ Public pricing pages reviewed in incognito on April 29, 2026
• ✅ Cancellation and refund policies read end-to-end on each provider site
• ✅ FDA approval dates and warning-letter history checked at FDA.gov
• ✅ Each provider’s formulary cross-referenced against their published material
• ⚠️ State availability claims are provider-stated — confirm at intake
• ⚠️ We did not independently lab-test compounded medication batches — that’s outside our scope
• ⚠️ Promo prices and intro offers shift frequently — re-verify at checkout

This isn’t another ranking page

If you’ve read three “best of” lists and still can’t pick, that’s because ranking pages can’t answer your question. They sort by who’s best on average. You’re asking who’s best for you.

We already publish Best GLP-1 Telehealth Providers (2026): Ranked & Reviewed for readers who want a leaderboard, The 7 Highest-Rated GLP-1 Providers in 2026 for trust-driven research, and Best Brand-Name GLP-1 Telehealth Providers if you only want FDA-approved options. Those pages serve different jobs.

This page exists for one job: nine real reader situations, mapped to one matched provider each, with the runner-up, the disqualifier, and what to verify before you commit. If even that feels like too much, the quiz takes 60 seconds and gives you the same answer faster.

Before you pick a provider — the one decision that changes everything

Every GLP-1 provider falls into one of two lanes: FDA-approved brand-name medication or compounded medication (pharmacy-prepared, not FDA-approved as a finished product). Pick the lane first. The provider almost picks itself after that.

What “FDA-approved” means (and what it costs)

FDA-approved means the drug went through full clinical trials, the manufacturing is controlled by the original drugmaker (Novo Nordisk for Wegovy and Ozempic; Eli Lilly for Zepbound, Mounjaro, and Foundayo), and your doctor knows exactly what’s in the bottle. Insurance coverage is possible but never guaranteed.

The FDA-approved GLP-1 medications used in 2026 weight-loss care are:

• Wegovy injection (semaglutide) — FDA-approved for chronic weight management
• Wegovy pill (oral semaglutide) — FDA-approved December 22, 2025; the first FDA-approved oral GLP-1 for weight loss in adults
• Wegovy HD 7.2 mg (higher-dose injection) — FDA-approved March 19, 2026; produced 20.7% mean body-weight reduction in the STEP UP trial
• Foundayo (orforglipron) — FDA-approved April 1, 2026; the newest oral weight-loss GLP-1
• Zepbound (tirzepatide) — FDA-approved for chronic weight management; pen, KwikPen, and single-dose vial formulations
• Ozempic (semaglutide) — FDA-approved for type 2 diabetes; may be prescribed off-label for weight loss
• Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes; may be prescribed off-label for weight loss

Cash-pay prices in 2026, verified April 29:

• Wegovy pill — $149/month for 1.5 mg and 4 mg through NovoCare Pharmacy and partner telehealth (Ro and others). The 4 mg offer at $149 runs through August 31, 2026, then moves to $199/month
• Wegovy pen (0.25 mg and 0.5 mg) — $199/month for the first two monthly fills through June 30, 2026 via NovoCare or Ro, then $349/month for standard maintenance doses
• Wegovy HD 7.2 mg — $399/month through NovoCare
• Zepbound KwikPen via Ro — $299/month for 2.5 mg, $399/month for 5 mg, $449/month for 7.5 mg–15 mg with Lilly’s manufacturer offer (refill within 45 days; missing the window can raise higher-dose refills meaningfully)
• Zepbound single-dose vials via LillyDirect — start at $299/month
• Foundayo via LillyDirect-matched pricing — $149–$299/month depending on dose

If you have commercial insurance and a Wegovy or Zepbound savings card, your copay can drop to as low as $25/month. Government beneficiaries (Medicare, Medicaid, TRICARE) are excluded from those manufacturer savings offers. The upside is huge if it works for you. The downside: insurance fights, prior authorizations, denials, and the specific feeling of being told your obesity isn’t “covered.”

What “compounded” means (and what it costs)

Compounded medications are prepared by state-licensed pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Per FDA’s April 2026 clarification, a 503A compounded drug must be prepared based on a prescription for an individual patient — and the compounder must not regularly compound products that are essentially copies of commercially available drugs unless a prescriber documents a significant clinical difference for that specific patient. Some providers use FDA-registered 503B outsourcing facilities, which are held to higher manufacturing standards.

Compounded GLP-1 programs cost roughly $129–$399/month cash, depending on the provider, formulation, and plan length.

Here’s the part you need to hear plainly.

Compounded GLP-1 medications are not FDA-approved. The FDA has not reviewed them for safety, effectiveness, or quality the way it reviews Wegovy or Zepbound. The FDA has issued specific safety communications about unapproved GLP-1 products, including dosing-error reports and quality concerns. We will not describe compounded products as “the same as” branded GLP-1s, “clinically proven,” or generic versions — they are none of those things by FDA’s definition.

That’s the damaging admission. Now the pivot.

For most cash-pay readers — the people who can’t get a $1,200/month brand-name medication covered by insurance and don’t want to give up on GLP-1 treatment because of price — a legitimate compounded program through a LegitScript-certified provider with a named pharmacy partner is the realistic on-ramp. Thousands of patients are accessing GLP-1 treatment this way in 2026, and the providers we feature below have built honest businesses around that reality. Pick a provider with a real medical evaluation, a named pharmacy, transparent pricing, and a cancellation policy you can find without a flashlight, and you’re choosing as carefully as anyone in this space can.

If “not FDA-approved” is a dealbreaker for you, stop reading the compounded sections below and go directly to the Ro persona — Ro is built for FDA-approved-only readers and we’ll route you there confidently. If you can hold both truths — that compounded is a real tradeoff and that it’s a defensible one for many situations — keep reading.

The 30-second test

• “I have commercial insurance” → FDA-approved lane (start with Ro)
• “I’m cash-pay and budget matters most” → Compounded lane (MEDVi, Eden, or Yucca depending on plan length)
• “I’m cash-pay but I want FDA-approved anyway” → FDA-approved lane at cash-pay prices through Ro, Hims/Hers, or NovoCare Pharmacy direct
• “I tried branded and want to switch to compounded for cost” → Compounded lane (Eden makes the switch easiest because they offer both)

Take the 60-second Provider Match Quiz

Five questions: insurance status, FDA-approved vs compounded preference, format preference, state, and budget tier. The quiz returns one matched provider plus a runner-up, with the reasoning shown so you can sanity-check the answer.

It exists because half the people who land on “best of” lists aren’t looking for a ranking — they’re looking for a recommendation calibrated to their situation. The quiz gives you that without forcing you to read this whole page first.

No medical info required. No prescription guaranteed. No payment up front.

The Right-Fit Matrix: 9 situations, 1 best match each (verified April 2026)

This is the spine of the page. Read down the Your situation column to find the row that describes you. The Best fit column tells you which provider was built for that situation. Runner-up is your second-best option if the first doesn’t work. What disqualifies is the dealbreaker that should send you elsewhere — and we’ll tell you where to go.

Pricing verified April 29, 2026. Sources: each provider’s public pricing page, Novo Nordisk press releases (Wegovy multi-month subscription program, March 31, 2026), Eli Lilly LillyDirect (Foundayo launch following April 1, 2026 FDA approval), and FDA approval announcements (Wegovy HD 7.2 mg, March 19, 2026). Compounded medications are not FDA-approved as finished products.

Which GLP-1 provider is right for me if I have commercial insurance?

The short answer: If you have commercial insurance and want FDA-approved Wegovy, Zepbound, or Foundayo with someone fighting for your coverage, Ro is the right starting point. Ro Body’s insurance concierge handles prior-authorization paperwork for members. They also offer a free GLP-1 Insurance Coverage Checker that contacts your insurance plan and reports back on coverage details — no payment, no commitment.

We hear it constantly: “Insurance denied it. I decided to go with compounded.” It’s the most common trigger that pushes people out of the FDA-approved lane. But here’s the thing — insurance denials are often appealable, especially with newer indications like Wegovy for cardiovascular risk reduction or Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Most telehealth platforms don’t have the appetite to fight that fight. Ro built their platform around it.

Free coverage checker vs. Ro Body insurance concierge

Worth understanding the difference, because it’s where most readers get tripped up:

• Free GLP-1 Insurance Coverage Checker — Available without enrollment. Ro contacts your insurance plan and reports your coverage details. Useful as a first step. Does not submit treatment requests or write prescriptions.
• Ro Body insurance concierge — Available to Ro Body members. Submits prior authorization requests, handles denial appeals when criteria support them, and routes you to LillyDirect-matched cash-pay prices if your insurance won’t cover the medication.

What Ro carries

• Foundayo (orforglipron) — FDA-approved April 1, 2026. $149–$299/month cash through Ro at LillyDirect-matched pricing
• Wegovy pill (oral semaglutide) — FDA-approved December 22, 2025. From $149/month cash; as low as $25/month with commercial insurance and Novo Nordisk’s savings card
• Wegovy pen (injectable semaglutide, including Wegovy HD 7.2 mg) — From $199/month cash on the new patient offer; $349/month for standard maintenance
• Zepbound pen, KwikPen, and single-dose vials (injectable tirzepatide) — From $299/month cash via the Lilly manufacturer offer
• Ozempic (semaglutide for type 2 diabetes; can be prescribed off-label)

The pricing math

Ro Body membership, verified April 29, 2026 on Ro.co/weight-loss/pricing:

Get started for $39, then as low as $74/month with annual plan paid upfront.

Standard ongoing membership is $149/month. Annual prepay drops it to as low as $74/month. Medication is priced separately — your cost depends on insurance coverage (could be your copay, as low as $25/month with a savings card) or LillyDirect / NovoCare-matched cash pricing.

The honest tradeoff

Ro is not the cheapest path if you only want a one-off prescription and don’t need help with insurance. The membership fee is real money on top of medication cost. If your insurance is straightforward and your doctor will prescribe Wegovy directly, you can skip Ro and use your existing pharmacy.

But Ro doesn’t try to be the cheapest one-off provider. They skipped that game so they could fund the insurance concierge — which is exactly what saves you $700+/month if you successfully get your medication covered. For people who actually want to use their insurance, the math wins.

Who Ro is NOT for

• Medicare or Medicaid patients (Ro generally doesn’t coordinate government insurance for GLP-1 except FEHB) → see persona #9 below
• Cash-pay readers who don’t want a membership fee → start with Eden or MEDVi
• Anyone who only wants compounded medication → Ro doesn’t lead in that lane

The next step is the free coverage checker. No payment, no commitment, just a coverage report.

Which GLP-1 provider is right for me if I’m cash-pay and want all-in support?

The short answer: If you want one transparent monthly price that bundles physician review, medication, shipping, and 24/7 provider access, MEDVi is the right answer. $179 for the first month of compounded semaglutide injections, with month-to-month flexibility and no contracts. LegitScript certified. 4.4 stars on Trustpilot across 12,600+ reviews as of April 2026.

This is the persona we hear most often. “I don’t have insurance. I can’t pay $1,200 for branded. I need a real doctor, real medication, and someone who picks up when I have side-effect questions at 11 p.m.” MEDVi was built for that reader.

Why MEDVi for this persona

• Bundled pricing. $179 first month covers your physician review, personalized treatment plan, metabolic report, your medication, and shipping. No separate consultation fee
• 24/7 provider access. Real licensed providers, not chatbots. The most-praised feature across MEDVi’s 12,600+ Trustpilot reviews
• Month-to-month flexibility — no long contracts, cancel anytime
• Both injection and tablet formats for both semaglutide and tirzepatide — most competitors offer injections only
• HSA/FSA eligible

MEDVi’s pricing menu (verified April 29, 2026)

• Compounded semaglutide injection — $179 first month, $299 refills
• Compounded semaglutide tablets — $249 first month, $369 refills
• Compounded tirzepatide injection — from $349
• Compounded tirzepatide tablets — from $279
• Brand-name Ozempic — premium-priced cash-pay (verify at checkout)

The honest tradeoff

Two facts a careful reader needs.

First: MEDVi received an FDA warning letter in February 2026 about misleading website claims — a labeling and marketing issue, not a medication-safety finding. We’re disclosing this because you’d find it eventually anyway, and you should weigh it.

Second: MEDVi’s official refund policy states there is no guarantee of results or effectiveness. Cancellation refunds are limited to specific circumstances such as medical disqualification. If you’ve seen claims of a “results-based money-back” guarantee elsewhere, verify the current terms in writing at checkout before assuming you’re protected. The realistic protection is that MEDVi runs month-to-month with no contracts, so you can cancel without losing future months.

There’s also a separate scientific question worth flagging if you’re considering oral tirzepatide tablets specifically — from MEDVi or any compounded provider:

Compounded oral tirzepatide is scientifically unresolved. Tirzepatide is a large peptide molecule (~4,813 daltons). The only FDA-approved oral GLP-1 (Rybelsus) required specialized SNAC absorption technology to reach roughly 1% bioavailability. There is no published clinical data showing compounded oral tirzepatide tablets achieve equivalent therapeutic absorption, and a November 2025 class-action complaint against OpenLoop Health and Triad Rx made this exact argument. If oral tirzepatide is what you want, ask your prescriber to discuss expected absorption and request the certificate of analysis for your batch. This applies to any compounded oral tirzepatide, not specifically to MEDVi.

If those facts move you to a different lane, that’s the right move — that’s why we’re showing them. MEDVi’s compounded semaglutide injection is well-characterized as a route of administration, but compounded products remain not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. If you want FDA-approved oral medication specifically, Ro carries the Wegovy pill and Foundayo — that’s your route, not compounded.

Who MEDVi is NOT for

• You want FDA-approved Zepbound or Mounjaro → Ro or Hims
• You’re set on compounded oral tirzepatide and won’t consider injectable → talk to your prescriber about absorption science before paying anyone
• You want the lowest possible price at maintenance dose → Yucca’s 6-month plan (persona #8)

If “cash-pay, transparent monthly pricing, well-supported, with the freedom to cancel anytime” describes you, this is the click.

Which GLP-1 provider is right for me if I want compounded and brand-name flexibility?

The short answer: If you want both compounded and brand-name GLP-1 options through one platform — plus protection against price hikes as you titrate up — Eden is the right answer. Eden’s compounded semaglutide is $129 first month / $209 ongoing on the 3-month plan, or $149 first month / $229 ongoing on the monthly plan. The “Same Price at Every Dose” guarantee means your bill won’t jump as your dosage increases — which is rarer than it should be in this category.

This persona is the reader who isn’t quite sure yet whether they want compounded or branded, and who wants the freedom to switch without changing providers.

Why Eden for this persona

• Same Price at Every Dose. Most GLP-1 providers start you on a low dose at attractive intro pricing, then bump your monthly cost as you titrate up. Eden locks your starting plan price for the duration. Over 12 months at maintenance dose, that can save several hundred dollars compared to dose-escalating providers
• Compounded plus brand-name under one platform. Start with compounded. If your situation changes — new job with insurance, you want to switch from semaglutide to Zepbound — Eden offers Wegovy, Ozempic, Zepbound, and Mounjaro alongside compounded options
• HSA/FSA accepted at checkout — direct, not reimbursement-only
• No membership fee for compounded plans
• 50 states through partner pharmacies licensed in all 50 states

Eden’s pricing (verified April 29, 2026)

Compounded:

• Compounded semaglutide injection — $129 first month / $209 ongoing on 3-month plan; $149 first month / $229 ongoing on monthly plan
• Compounded tirzepatide — verify current pricing at checkout

Brand-name (Eden’s published list prices):

• Ozempic — $1,399/month
• Mounjaro — $1,399/month
• Zepbound — $1,399/month
• Wegovy — $1,695/month

These brand-name prices reflect Eden’s listed cash prices and are higher than what you’d pay through Ro, NovoCare Pharmacy direct, or Hims/Hers’s manufacturer-collaboration pricing. If branded medication is your destination, start with Ro instead. Eden’s value is in the compounded program and the freedom to switch later.

Reported results

Eden members reported an average weight loss of 29.3 pounds in the first six months, based on self-reported data from 111 members on GLP-1 injections combined with diet and exercise. Individual results vary; this is provider-stated, member-reported data, not a clinical trial.

The honest tradeoff

Eden isn’t the cheapest provider on this page. Yucca Health’s 6-month plan saves you about $50–$60/month at maintenance dose. If lowest absolute cost is your only metric, Yucca wins.

But Yucca doesn’t offer brand-name medication, doesn’t include 24/7 messaging, and locks you into 6 months — and if you bail at month 2, you’ve prepaid the rest. Eden gave up “absolute cheapest” so it could fund the dose-escalation guarantee, the brand-name option, and the support layer. For most readers who don’t already know they’re settled on the cheapest possible path, Eden is the broader option with fewer regrets.

Who Eden is NOT for

• Lowest first-month price is the only thing that matters → Yucca
• You want bundled all-in pricing with 24/7 support included → MEDVi
• You want insurance-fight support → Ro

If “predictable pricing, the option to switch later, no membership fee” describes you:

Compare Eden head-to-head with Hers, Hims, or MEDVi if you want the deeper dive.

Which GLP-1 provider is right for me if I don’t want to inject?

The short answer: Needle-free GLP-1 access splits into two paths in 2026. For FDA-approved oral medication (the safer choice if you can afford it), Ro carries the Wegovy pill (from $149/month) and Foundayo (from $149/month). For compounded no-injection options, SHED offers GLP-1 lozenges from $199/month.

Needle-aversion is a legitimate reason to take a different path — but the absorption science is genuinely different across formats, and you should know that before you choose.

Path A: FDA-approved oral GLP-1s through Ro

• Wegovy pill (oral semaglutide) — FDA-approved December 22, 2025. The first FDA-approved oral GLP-1 for weight loss. Cash-pay $149/month for 1.5 mg and 4 mg. With commercial insurance and Novo Nordisk’s savings card, your cost can drop to as low as $25/month
• Foundayo (orforglipron) — FDA-approved April 1, 2026. The newest oral weight-loss GLP-1, and the only one you can take any time of day, with or without food. Cash-pay $149–$299/month through Ro at LillyDirect-matched pricing

These are FDA-approved products. The absorption is established. The dosing is clinically validated. If you can pay $149/month — or use insurance — this is the safer needle-free path.

Path B: Compounded no-injection formats

If FDA-approved oral isn’t an option for you, the verified compounded paths in 2026:

• SHED publishes GLP-1 lozenges starting at $199/month — a needle-free compounded option with online signup and home delivery
• Willow offers a sublingual semaglutide tablet (verify current pricing and state availability at intake)
• TrimRX offers oral compounded semaglutide (verify current pricing and program terms at intake)

The honest tradeoff: don’t conflate compounded oral with FDA-approved oral

Compounded oral semaglutide drops, sublingual tablets, and lozenges are different products from the FDA-approved Wegovy pill or Foundayo. They use different formulations and delivery methods. The FDA has not reviewed them for safety, effectiveness, or quality, and the FDA has issued specific warnings about misleading “same as Wegovy” claims around compounded GLP-1 products. We will not describe them as equivalent and you shouldn’t assume they are.

If absorption certainty matters to you (and at $200–$300/month, it should), the FDA-approved path through Ro is the higher-confidence choice. If you can’t afford FDA-approved or specifically want a compounded option, the providers above are legitimate options — but go in with eyes open.

Which GLP-1 provider is right for me if I want a familiar mainstream brand?

The short answer: If you want a polished, familiar, app-driven brand experience and FDA-approved Wegovy, Zepbound, Foundayo, or Ozempic, Hims (men) and Hers (women) became legitimate options in 2026. Following the strategic shift announced in March 2026 and a Novo Nordisk collaboration that brings authentic FDA-approved Wegovy and Ozempic onto the platform, Hims & Hers is now an authorized distribution channel for those Novo medications, alongside Eli Lilly’s Zepbound and Foundayo.

What changed in early 2026

Quick recap because the landscape moved fast:

• February 2026: Novo Nordisk and Hims & Hers had a high-profile patent dispute over compounded oral semaglutide
• March 9, 2026: Companies settled. Hims agreed to sell branded Novo Nordisk products directly. Hims agreed to wind down advertised compounded semaglutide except in narrow clinically-necessary cases
• March 31, 2026: Novo Nordisk launched its multi-month Wegovy subscription program through Ro, WeightWatchers, LifeMD, with Hims & Hers added subsequently

Hims & Hers is now an authorized distribution channel for Novo Nordisk’s semaglutide lineup. The platform also offers Eli Lilly’s Zepbound and Foundayo — though note that the Novo Nordisk collaboration applies specifically to Novo products (Wegovy and Ozempic), not Lilly products. Hims publicly states it is not affiliated with or endorsed by Eli Lilly.

Hims & Hers pricing structure (verified April 29, 2026)

Hims and Hers price medications and the platform membership separately:

Medication-only pricing (from $X/month — verify at checkout):

• Wegovy pen — from $199/month
• Wegovy pill — from $149/month
• Wegovy HD 7.2 mg — verify current availability
• Zepbound vial / KwikPen — from $299/month
• Foundayo — from $149/month
• Ozempic — from $199/month

Plus a separate Weight Loss Membership: $39 first month, then $149/month ongoing.

Important state caveat: Hims and Hers explicitly state their weight-loss programs are not available in all 50 states. Confirm availability during intake before committing.

The honest tradeoff

Hims & Hers’s value is the brand familiarity, the app, and access to authentic FDA-approved Wegovy through the Novo Nordisk collaboration. The total cost (medication + membership) is competitive with Ro for cash-pay readers — they’re roughly comparable for FDA-approved access. Where they differ:

• Ro’s edge: stronger insurance concierge, more focus on prior-authorization paperwork, the GLP-1 Insurance Coverage Checker, longer track record in this category
• Hims/Hers’s edge: stronger consumer brand recognition, polished mobile app experience, men’s-only and women’s-only product lines

If you want the lowest cash cost on compounded semaglutide, Hims’s strategic shift away from compounded means Eden, MEDVi, or Yucca will save you significant money on that path.

Who Hims/Hers is NOT for

• You want compounded semaglutide cheaper than $200/month → Eden, MEDVi, or Yucca
• You want an insurance concierge that actively fights for prior-authorization → Ro
• You live in a state Hims/Hers doesn’t serve → Ro or NovoCare Pharmacy

If you want the mainstream-brand experience and FDA-approved Wegovy, Zepbound, or Foundayo:

Which GLP-1 provider is right for me if I want lab-guided care?

The short answer: If you’ve plateaued on semaglutide, want stronger tirzepatide-forward protocols, or just want a more hands-on premium-feeling clinical experience with regular lab monitoring, Enhance MD is the right answer. They offer compounded semaglutide, tirzepatide, and combination “Elite” plans with metabolic lab testing every 6 months and same pricing across all dose levels.

This persona isn’t most readers. But if you’ve already done a few months on a basic compounded program and felt under-supported — or if you’re someone who wants regular labs from day one — Enhance MD is built for that reader.

Why Enhance MD for this persona

• Tirzepatide-forward protocols designed for plateau response or higher-baseline-BMI readers
• Combination plans (semaglutide + tirzepatide protocols, available where clinically appropriate)
• Metabolic lab testing built into the program at 6-month cycles
• Same pricing across all dose levels — your bill doesn’t escalate as you titrate
• Free shipping included
• Plan structures from approximately $189 first month / $322 ongoing on 12-month billing for the Elite combination plan; verify current dose-specific pricing at checkout

The honest tradeoff

Enhance MD isn’t the cheapest path. If lowest cost is your priority, this isn’t your provider. They’ve positioned themselves as the upgrade tier — for readers who’ve already tried lower-priced compounded providers and want more hands-on care, or for readers who want labs and structured monitoring from the start.

Who Enhance MD is NOT for

• You want lowest possible monthly cost → Yucca, MEDVi, or Eden
• You want FDA-approved Zepbound or Mounjaro specifically → Ro
• You want minimal touch and just the medication → MEDVi or Yucca

Which GLP-1 provider is right for me if budget is the only thing that matters?

The short answer: If you’re cash-pay and absolute lowest monthly cost matters more than every other feature, Yucca Health is your provider. Yucca publicly lists compounded semaglutide as low as $146/month for new patients on the 6-month plan and tirzepatide as low as $258/month for new patients on the same plan structure. UPS 2-Day Air shipping included. 50 states.

This is a smaller persona than the others, but a real one. If you’ve already decided you want to be on GLP-1 for the long haul and you’ve decided cost is the constraint that matters most, Yucca’s math wins.

Yucca’s pricing structure (verified April 29, 2026)

• Compounded semaglutide — as low as $146/month for new patients on the 6-month plan
• Compounded tirzepatide — as low as $258/month for new patients on the 6-month plan
• BNPL options including Klarna, Affirm, and Afterpay
• Free UPS 2-Day Air shipping
• 50 states (provider-stated; confirm at intake)
• Provider review within 24 hours
• “Only charged if prescribed” language at intake

The honest tradeoff (this matters for Yucca specifically)

Yucca strips out the things that drive other providers’ prices up — no 24/7 messaging support, no built-in coaching app, no brand-name option. The 6-month plan delivers the lowest pricing — and Yucca’s compounded prescriptions are final sale once shipped. If you bail at month 2, you’ve already paid for what shipped. That’s a real tradeoff.

If you’re not 100% sure GLP-1 will work for your body and you want flexibility, MEDVi’s month-to-month is worth the slightly higher price. If you’re confident you’re in this for at least 6 months and “minimum monthly cost” is your highest priority, Yucca wins on math.

Who Yucca is NOT for

• You want 24/7 messaging support → MEDVi or Eden
• You want flexibility to cancel mid-treatment → MEDVi (month-to-month)
• You want a brand-name medication option → Eden, Ro, or Hims/Hers

Which GLP-1 provider is right for me if I have Medicare or Medicaid?

The short answer: Medicare coverage for GLP-1 medications is changing meaningfully in 2026. CMS announced the Medicare GLP-1 Bridge, which gives eligible Part D beneficiaries access to certain GLP-1 medications for weight reduction at a $50 monthly copay from July 1, 2026 through December 31, 2027. Covered products include Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen. This is on top of existing Part D coverage that may apply for non-weight-loss indications — Wegovy for major adverse cardiovascular event risk reduction, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

This is the most important Medicare/Medicaid update we’ve seen in this category. If you’re a Medicare beneficiary who’s been told for years that GLP-1s for weight loss aren’t covered, that changes mid-2026 for the conditions and medications listed above.

Your strongest paths in 2026

• Existing Part D coverage for cardiovascular or sleep apnea indications (talk to your doctor about whether you qualify under current criteria)
• Medicare GLP-1 Bridge starting July 1, 2026 — covers Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen for weight reduction at a $50 copay for eligible Part D beneficiaries
• NovoCare Pharmacy direct for cash-pay Wegovy access
• Sesame Care for branded medication access with provider choice and cash-pay pricing options
• Form Health — accepts most major private insurances and Medicare for care-team visits, labs, and medications
• Your in-person primary care physician or endocrinologist for direct prescribing under your existing coverage

What most major telehealth platforms can’t do for you

Most cash-pay-focused platforms (MEDVi, Eden, most compounded providers) don’t coordinate Medicare or Medicaid coverage for GLP-1 medications. Ro generally can’t either, except for FEHB plans. That’s not a knock on those providers — government insurance coordination is genuinely complex — but it means your starting line is different than for commercially-insured readers.

Who’s right for you

If you have Part D and your indication is cardiovascular or OSA, talk to your physician about existing coverage. If you’re waiting on the Medicare GLP-1 Bridge for weight-reduction coverage, July 1, 2026 is the start date — and you should confirm eligibility through your plan and CMS.gov closer to launch. For cash-pay branded access in the meantime, Sesame Care and NovoCare Pharmacy direct are the cleanest paths.

For our deeper guides, see GLP-1 Providers That Accept Medicare and GLP-1 Providers That Accept Medicaid.

How to verify any GLP-1 provider is legitimate (5-point safety check)

The short answer: Before you pay any GLP-1 provider — including the ones we feature above — verify five things: (1) they require a real medical evaluation, (2) they name their compounding pharmacy partner, (3) they’re LegitScript certified, (4) they explicitly disclose that compounded medications are not FDA-approved, and (5) full pricing including cancellation terms is visible before payment. Any provider missing two or more is a walk-away.

We hear this fear constantly: “There are so many GLP-1 provider websites now, it’s all so confusing to navigate. These companies are so vague on purpose.” Real reader, real frustration. Vagueness is a tactic — it’s how illegitimate operators hide. Here’s the checklist that surfaces them.

The 5-point legitimacy checklist

1. Real medical evaluation required. A health questionnaire reviewed by a licensed clinician is the minimum. Any platform offering GLP-1s without an evaluation is operating illegally — walk away
2. Named pharmacy partner. A legitimate provider names the state-licensed pharmacy or FDA-registered 503B outsourcing facility that fills your prescription. If you can’t find that name in their FAQ, terms of service, or support, that’s a problem
3. LegitScript certified. LegitScript.com independently verifies online healthcare companies. The National Association of Boards of Pharmacy (NABP) has reported that roughly half of the illegal online pharmacies they investigated were selling semaglutide products. Search any provider before paying
4. Compounded-not-FDA-approved disclosure. A legitimate compounded GLP-1 provider says it plainly. They don’t call compounded medication “FDA-approved” or “the same as Wegovy” or “generic Ozempic.” If a provider blurs that line in their marketing, the FDA’s safety communications may already apply to them
5. Full pricing visible before checkout. Month one price, ongoing monthly price, dose-based price changes, membership fees, cancellation terms — all visible before payment. If any of those is buried, that’s by design and not in your favor

Red flags that should make you walk away

• “No prescription required” (illegal for GLP-1 medications)
• “Research use only” (FDA has specifically warned about this)
• “Same as Wegovy / Ozempic / Zepbound” (FDA misbranding territory)
• “Guaranteed approval” (no legitimate provider guarantees a prescription before evaluation)
• Hidden subscription fees or auto-renewal traps
• No named pharmacy partner
• Cancellation buried or impossible to find

Verify any provider in 60 seconds

• LegitScript: legitscript.com — search the provider’s name
• FDA BeSafeRx: fda.gov BeSafeRx
• NABP: nabp.pharmacy
• FDA warning letter database: search the provider name to see if any actions have been taken

We do this for every provider featured on our site. We continue to feature providers who have received warning letters for labeling/marketing issues (not medication safety) when those providers operate transparently and meet the rest of our verification standards. We disclose those facts plainly so you can make your own call.

If running these checks yourself feels like more work than it should be, the quiz does the filtering for you — only providers we’ve verified appear in the results.

How to compare true cost (not just sticker price)

The short answer: The cheapest first-month price isn’t the cheapest provider. True GLP-1 program cost is the total of membership fee + medication cost + labs + shipping + visit fees + dose-related price changes + the cost of the commitment if you bail early. Compare on that, not on the headline.

This is where most readers get fooled. A $99 first-month offer with a $149/month membership tacked on is more expensive than a $179 all-in first month. A $146/month plan that locks you into 6 months prepaid is genuinely the cheapest only if you stay 6 months — otherwise it’s the most expensive.

The True-Cost Formula

True monthly cost = (membership fee + medication cost + lab fees + shipping + dose-escalation surcharge) × commitment exposure

What to add up before comparing

• Membership / consult fee (separate from medication) — Ro Body $74–$149/month, Hims/Hers $39 first month then $149/month, Eden $0 (compounded), Lemonaid $49/month
• Medication cost — varies by dose, formulation, and provider
• Dose-escalation pricing — does the price change as you titrate up? (Eden = no, Same Price at Every Dose; many compounded providers = no on injection, tiered on tablets vs injection; some = yes, big jump at maintenance)
• Lab fees — included? required? optional? Quest Diagnostics included is common for higher-tier programs
• Shipping — included or extra
• Cancellation friction — final sale once shipped (Yucca), month-to-month (MEDVi), prepay-only with no refund (most 3-month and 6-month plans)
• Hidden fees — separate consultation charges, dose-change fees, refill processing

Year-one cost estimates for compounded semaglutide injection

Pricing as of April 29, 2026 from each provider’s pricing page. Excludes optional labs, supplements, branded medication paths, and price changes that may occur during the year. Compounded medications are not FDA-approved. Verify current pricing before enrolling.

The math says: if you can commit to Yucca’s 6-month plan and stay, it’s the cheapest year-one path. Eden’s 3-month plan is the cheapest path with shorter commitment. MEDVi month-to-month gives you the most flexibility but costs the most over a year if you stay long-term — that flexibility is what some readers need, though.

If you’re unsure which math applies to your situation, run it through the quiz — it factors in commitment tolerance, not just first-month price.

Real scenarios — based on what readers actually tell us

This section is for readers who don’t think in personas. They think in trigger moments. Sound familiar?

“Insurance denied my Wegovy or Zepbound.”

Most common path:

1. Don’t give up on insurance yet. Many denials are appealable, especially for newer indications (Wegovy for cardiovascular risk reduction; Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity). Ro’s insurance concierge handles the appeal as part of Ro Body membership
2. While appealing, check whether you qualify for the Wegovy Savings Offer or Zepbound Savings Card — commercial insurance plus a savings card can drop your copay to as low as $25/month
3. If you’ve exhausted insurance, the cash-pay path through Ro at LillyDirect / NovoCare-matched pricing keeps you on FDA-approved medication. Wegovy pill at $149/month is often achievable
4. If branded cash-pay is still unaffordable, that’s when you switch lanes — to compounded through MEDVi, Eden, or another verified provider

We have a dedicated guide: Wegovy Prior Authorization Denied? What To Do Next.

“I don’t have insurance and can’t pay multiple months upfront.”

Most common path:

1. MEDVi month-to-month ($179 first month, $299/month ongoing) is the most flexible no-prepay path. You can cancel anytime
2. Eden monthly plan ($149 first month, $229/month ongoing) is your second option. The Same Price at Every Dose guarantee protects your bill from creeping up as you titrate
3. Avoid 6-month prepay plans if you’re not certain you’ll stay — Yucca’s lower rate is real, but commitment is real too (final sale once shipped)
4. Use HSA/FSA at checkout if you have it (Eden, MEDVi, and Ro all accept)

“The pricing on these sites looks confusing. I don’t know what I’d actually pay.”

Most common path:

1. Read the Total Cost section above — write down the membership fee, medication cost, dose escalation, and shipping for any 2–3 providers you’re comparing
2. The clearest-pricing providers we verified: MEDVi (one bundled price for compounded plans), Eden (Same Price at Every Dose), Yucca (transparent 6-month math)
3. The hidden-fee categories most readers miss: dose-escalation surcharges, 28-day vs 30-day billing cycles, separate consultation fees, “first month” promo expirations. Our GLP-1 Providers With No Hidden Fees audit breaks all of this down

“I’m afraid I’ll choose wrong and either get scammed or stuck.”

Most common path:

1. Run the 5-point legitimacy check above on your top 2 providers
2. Search them on LegitScript.com
3. Pick a provider with a real cancellation policy so you have an exit if it doesn’t work for your body — MEDVi’s month-to-month is the lowest-friction option
4. Take the 60-second Match Quiz — it filters the red flags for you and only matches you to providers we’ve verified

“I want a familiar brand, not a startup I’ve never heard of.”

Most common path:

1. Hims (men) / Hers (women) are publicly traded (NYSE: HIMS), have a Novo Nordisk collaboration for FDA-approved Wegovy and Ozempic, and operate a polished app experience. As of 2026 they’re a legitimate FDA-approved retailer
2. Ro has been operating since 2017, has a strong insurance concierge, and carries the full FDA-approved formulary including Foundayo
3. Walgreens Weight Management is also a path if you specifically want a national pharmacy chain

How we score and what we will and won’t do

The short answer: We score GLP-1 providers across seven categories using a weighted rubric. Provider fit (does this provider match the reader’s specific situation?) is the largest single category at 25% — because a provider that fits the wrong reader well still leaves the right reader stuck.

Provider Fit Score (100 points)

What we will not do

• We will not call compounded GLP-1 medications “FDA-approved.” They aren’t
• We will not say compounded products contain the “same active ingredient” as Wegovy or Zepbound, or that they’re “clinically proven” to produce equivalent results. The FDA has specifically warned about that language
• We will not use star ratings or AggregateRating schema for providers we haven’t independently rated with a first-party rubric
• We will not imply testimonials prove medical efficacy or that any specific weight-loss result is typical
• We will not hide regulatory warnings, even for providers we’re affiliated with
• We will not guarantee a prescription. No legitimate provider should

What we will do

• We re-verify pricing and policies monthly. The “Last verified” date at the top of this page reflects the most recent round
• We disclose affiliate relationships on every page that has them
• We update sections when material facts change (FDA actions, settlements, formulary changes, the new Medicare GLP-1 Bridge, etc.)
• We tell you who each provider is not for, and route you to internal alternatives when our featured pick doesn’t fit your situation

Frequently asked questions

Which GLP-1 provider is best in 2026?

There is no single best provider for everyone. The right one depends on your situation. For commercial insurance and FDA-approved access, Ro is strongest. For all-in cash-pay pricing with 24/7 support and month-to-month flexibility, MEDVi. For brand-name plus compounded flexibility under one roof with the Same Price at Every Dose guarantee, Eden. For familiar mainstream branded experience, Hims or Hers. For lab-guided premium care, Enhance MD. For absolute lowest cash cost on a 6-month plan, Yucca Health.

Which GLP-1 provider is cheapest without insurance?

Based on verified April 2026 pricing, Yucca Health’s 6-month plan ($146/month) is the cheapest verified entry for compounded semaglutide if you can commit to 6 months. Eden’s 3-month plan ($129 first month / $209 ongoing) is the cheapest path with shorter commitment. MEDVi’s month-to-month ($179 first month, $299 ongoing) is the most flexible. Compare total annual cost — not first-month price — before choosing.

How do I choose between compounded and FDA-approved GLP-1?

If you have commercial insurance and your plan covers Wegovy, Zepbound, Mounjaro, Ozempic, or Foundayo, choose FDA-approved through Ro — your copay can drop to as low as $25/month with a manufacturer savings card (government beneficiaries excluded). If you’re paying cash and brand-name pricing isn’t workable, compounded ($129–$399/month through verified providers) is the realistic path. Compounded medications are not FDA-approved as finished products, but legitimate providers prepare them through state-licensed 503A pharmacies under clinician oversight.

Can I get a GLP-1 prescription online?

Yes. Every legitimate provider in the matrix above connects you with a licensed physician who reviews your medical history and writes a prescription if treatment is appropriate. The process is virtual but a real evaluation is required. Any platform offering GLP-1s without an evaluation is illegal and a walk-away.

Are compounded GLP-1 medications safe?

Compounded GLP-1 medications are not FDA-approved as finished products and have not been reviewed for safety, effectiveness, or quality the way Wegovy or Zepbound have been. The FDA has issued specific safety communications about unapproved GLP-1 products. When prepared by state-licensed pharmacies or FDA-registered 503B outsourcing facilities following USP standards, quality is more controlled — but the risk profile is genuinely different from FDA-approved versions, and you should weigh that before choosing.

Does Medicare cover GLP-1 medications for weight loss?

Medicare coverage is changing in 2026. The new Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen for weight reduction at a $50 monthly copay from July 1, 2026 through December 31, 2027. Existing Part D coverage may also apply for non-weight-loss indications such as Wegovy for cardiovascular event risk reduction or Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Confirm eligibility with your Part D plan and on CMS.gov.

Which GLP-1 provider works in my state?

State availability varies by provider. Eden states it works with pharmacies licensed in all 50 states. Yucca Health states 50-state coverage. Hims and Hers explicitly state their weight-loss programs are not available in all 50 states. MEDVi state availability should be confirmed at intake. Always verify before paying.

What’s the difference between Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo?

Wegovy and Ozempic both contain semaglutide. Wegovy is FDA-approved for chronic weight management; Ozempic is FDA-approved for type 2 diabetes (may be prescribed off-label for weight loss). Zepbound and Mounjaro both contain tirzepatide. Zepbound is FDA-approved for chronic weight management; Mounjaro is FDA-approved for type 2 diabetes (may be prescribed off-label for weight loss). Foundayo (orforglipron) is the newest oral GLP-1 specifically FDA-approved for weight loss, approved April 1, 2026. Wegovy pill, the oral form of semaglutide approved December 22, 2025, was the first FDA-approved oral GLP-1 for weight loss.

Should I pick the cheapest provider?

Not necessarily. The cheapest provider on our matrix (Yucca Health, $146/month) is also the most committed (6-month plan, final sale once shipped, no 24/7 support). The right question is “cheapest provider that fits the rest of my situation,” not “cheapest in absolute terms.” For most readers, MEDVi or Eden are better total value than Yucca despite costing more per month — the support layer and flexibility add real value when you actually need them.

What if I’m pregnant, planning pregnancy, or have a thyroid cancer family history?

GLP-1 medications carry a boxed warning for thyroid C-cell tumors and should not be used by anyone with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are also not appropriate during pregnancy or while nursing. A licensed clinician should review your full medical history before prescribing — and any provider that approves you without screening for these conditions is operating below safety standard.

How do I cancel if a provider doesn’t work out?

Read the cancellation policy before you pay. Look for: (1) is cancellation visible on the provider’s site, (2) is it month-to-month or commitment-locked, (3) what happens to medication already shipped (most compounded prescriptions are final sale), and (4) what refund pathways exist. MEDVi runs month-to-month with no contracts. Eden’s monthly plan can be canceled anytime. Yucca’s 6-month commitment is real, and final sale applies once your prescription ships.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

If you’ve read this far and still aren’t sure which row of the matrix describes you, the quiz will sort it. Five questions. One matched provider. Full reasoning shown so you can sanity-check the answer. No medical info required.

You’re not picking forever. You’re picking your starting point. Most providers on this page let you switch later if your situation changes. The right move now is to start with the provider that fits this week’s situation, and trust that the path becomes clearer once you’re in motion.

Sources & references

1. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384:989–1002. (STEP 1 trial — semaglutide 14.9% body-weight loss over 68 weeks.) NEJM link
2. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205–216. (SURMOUNT-1 trial — tirzepatide up to 20.9% body-weight loss.) NEJM link
3. Aronne LJ, et al. “Tirzepatide vs Semaglutide for Weight Loss in Adults with Obesity.” NEJM/ACC. 2025. (SURMOUNT-5 head-to-head.)
4. STEP UP trial — Wegovy HD 7.2 mg, 20.7% mean body-weight reduction. FDA-approved March 19, 2026.
5. U.S. Food and Drug Administration. “FDA Approves First New Molecular Entity Under National Priority Voucher Program.” (Foundayo / orforglipron approval, April 1, 2026.)
6. U.S. Food and Drug Administration. “FDA’s Concerns About Unapproved GLP-1 Drugs Used for Weight Loss.” FDA safety alert
7. U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” (April 2026.)
8. Centers for Medicare & Medicaid Services. “Medicare GLP-1 Bridge.” (CMS.gov)
9. Novo Nordisk press release. “First and only multi-month subscription program for FDA-approved Wegovy.” March 31, 2026.
10. NovoCare Pharmacy. Wegovy pen and Wegovy tablet self-pay pricing. NovoCare.com (verified April 29, 2026).
11. National Association of Boards of Pharmacy (NABP). “Half of Illegal Online Pharmacies Selling Semaglutide Products.”
12. Provider pricing pages, all verified April 29, 2026: Ro.co/weight-loss/pricing, MEDVi.org, TryEden.com, ForHims.com, ForHers.com, TryShed.com, Enhance.MD, TryYucca.com, MyStartHealth.com, SesameCare.com, FormHealth.co.

Editorial: This guide was produced by the Weight Loss Provider Guide Research Team — an independent comparison resource for GLP-1 telehealth providers. Reviewed by our editorial team. Last verified April 29, 2026.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved as finished products. Always consult a qualified healthcare professional before starting any weight-loss medication. A prescription is never guaranteed.

Affiliate disclosure: Weight Loss Provider Guide may receive compensation when you click links on this page and purchase from our partner providers. Rankings and recommendations are based on our 100-point scoring methodology. We rank by reader fit, not payout.